ClinicalTrials.gg
RecruitingNCT07456020AssessConscUpdated Mar 11, 2026

Assessment of Consciousness With CRS-R and SECONDs

An observational study in Disorders of Consciousness Due to Severe Brain Injury, Minimally Conscious State and Unresponsive Wakefulness Syndrome, sponsored by BDH-Klinik Hessisch Oldendorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by BDH-Klinik Hessisch Oldendorf · Observational

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Study summary

Accurately determining the level of consciousness in patients with severe brain injury is essential for treatment planning, prognosis, and ethical decision-making. Clinically, levels of consciousness are differentiated into coma, Unresponsive Wakefulness Syndrome (UWS), and Minimally Conscious State (MCS) based on behavioral signs. Although behavioral assessment is considered the clinical gold standard, it is prone to misclassification. Research has shown that a substantial proportion of patients initially diagnosed with UWS may actually show signs of minimal consciousness, which is associated with better cognitive abilities and a more favorable prognosis.

The Coma Recovery Scale-Revised (CRS-R) is internationally recommended for diagnosing disorders of consciousness, but it is time-consuming and not free from diagnostic error. Repeated assessments can significantly improve diagnostic accuracy. To enhance feasibility in routine clinical practice, a shorter and more time-efficient assessment tool, the Simplified Evaluation of CONsciousness Disorders (SECONDs), was developed. This scale focuses on the behavioral signs most strongly associated with MCS and uses optimized testing procedures while maintaining high diagnostic accuracy.

The aim of this study is to further evaluate diagnostic approaches for assessing consciousness in patients with severe brain injury and to improve the reliability and clinical applicability of these assessments.

Read the detailed description

This prospective observational study is designed to evaluate the clinical utility and diagnostic performance of the Simplified Evaluation of CONsciousness Disorders (SECONDs) in a neurological rehabilitation setting. The study aims to assess whether the implementation of SECONDs improves diagnostic accuracy in patients with disorders of consciousness during the subacute phase after severe acquired brain injury.

Participants will undergo structured behavioral assessment using SECONDs as part of the study protocol. Diagnostic classifications derived from SECONDs will be analyzed with regard to their internal consistency and clinical plausibility within the rehabilitation context.

To examine prognostic validity, functional outcome will be assessed 12 months after the initial evaluation. Follow-up data will be collected through structured telephone interviews with relatives or legal representatives. Functional status will be systematically documented in order to determine the predictive value of SECONDs classifications for long-term clinically relevant outcomes.

The study seeks to contribute to optimizing diagnostic procedures in disorders of consciousness and to strengthen the evidence base for time-efficient behavioral assessment tools in routine neurorehabilitation practice.

02

Conditions studied

  • Disorders of Consciousness Due to Severe Brain Injury
  • Minimally Conscious State
  • Unresponsive Wakefulness Syndrome

Keywords

  • Disorders of consciousness
  • Coma Recovery Scale-Revised
  • SECONDs
  • Acquired Brain Injury
  • Neurological rehabilitation
  • Critical ill patients
03

In context

Persistent Vegetative State

88 studies on the registry are indexed under Persistent Vegetative State; 20 are open to participants now.

This study's planned enrollment of 110 is above the median of 80 across 31 observational studies indexed under Persistent Vegetative State.

Browse Persistent Vegetative State studies →

Lead sponsor

BDH-Klinik Hessisch Oldendorf is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of adult patients with severe acquired brain injury admitted to a neurological early rehabilitation program. Eligible participants present with a disorder of consciousness in the subacute phase (within 90 days after the index event) and require intensive or monitored medical care. Underlying etiologies include anoxic, traumatic, or vascular brain injury. Patients are characterized by severe functional impairment, as reflected by a low Early Rehabilitation Barthel Index score at admission.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission to an intensive care unit (ICU) or intermediate/high-dependency care unit
  • Underlying etiology of brain injury: anoxic, traumatic, or vascular
  • Time since index event \< 90 days
  • Early Rehabilitation Barthel Index (ERBI) score \< 30 points

Exclusion criteria

Exclusion Criteria:

  • History of prior brain injury
  • Pre-existing major psychiatric disorder
  • Impaired language comprehension (e.g., insufficient German language proficiency or aphasia)
  • Ongoing sedation at the time of assessment
  • Interruption of rehabilitation treatment (transfer to an acute care hospital) for more than 14 days
  • isolation precautions due to multidrug-resistant organisms
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Disorders of Consciousness

    Adult patients with severe acquired brain injury diagnosed with a disorder of consciousness (e.g., unresponsive wakefulness syndrome or minimally conscious state) undergoing structured behavioral assessment in a neurological rehabilitation setting.

    Behavioral: Simplified Evaluation of CONsciousness Disorders (SECONDs) · Behavioral: Coma Recovery Scale-Revised (CRS-R)

Interventions

  • BehavioralSimplified Evaluation of CONsciousness Disorders (SECONDs)

    The Simplified Evaluation of CONsciousness Disorders (SECONDs) is a structured behavioral assessment tool designed for the rapid evaluation of patients with disorders of consciousness.

  • BehavioralComa Recovery Scale-Revised (CRS-R)

    The Coma Recovery Scale-Revised (CRS-R) is a standardized behavioral assessment tool used to evaluate the level of consciousness in patients with severe brain injury. It consists of six subscales assessing auditory, visual, motor, oromotor/verbal, communication, and arousal functions.

06

What researchers measure

Primary outcomes

  1. Agreement Between the "Simplified Evaluation of CONsciousness Disorders" (SECONDs; Range: 0-8) and the "Coma Recovery Scale-Revised" (CRS-R; Range: 0-23)

    Categorical agreement in clinical classification of level of consciousness (Unresponsive Wakefulness Syndrome \[UWS\], Minimally Conscious State \[MCS\], Emerged from Minimally Conscious State \[eMCS\], No Disorder of Consciousness \[non-DoC\]) between the Simplified Evaluation of CONsciousness Disorders (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).

    Time frame: 6-8 days after admission to neurological rehabilitation

Secondary outcomes

  1. Diagnostic Stability in Patients Initially Classified as UWS

    Rate of diagnostic reclassification following repeated behavioral assessment on two consecutive days in patients initially diagnosed with Unresponsive Wakefulness Syndrome (UWS). Misdiagnosis rate is defined as the proportion of patients whose level of consciousness is reclassified into a different diagnostic category (e.g., from UWS to Minimally Conscious State \[MCS\]) upon repeat measurement.

    Time frame: 6-8 days after admission to neurological rehabilitation

  2. Prognostic Validity of the "Simplified Evaluation of CONsciousness Disorders" (SECONDs; Range: 0-8) for Long-Term Functional Outcome

    Predictive value of baseline classification using the Simplified Evaluation of CONsciousness Disorders (SECONDs; ; Range: 0-8) for functional outcome at 12 months after admission, as measured by the Glasgow Outcome Scale-Extended (GOSE; Range: 1-8).

    Time frame: 12 months after admission.

  3. Feasibility of the Simplified Evaluation of CONsciousness Disorders (SECONDs)

    Assessment of clinical feasibility of SECONDs in a neurological rehabilitation setting, including test completion rate, administration time per assessment, and occurrence of premature test termination or technical/practical difficulties.

    Time frame: 6-8 days after admission to neurological rehabilitation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wannez S, Heine L, Thonnard M, Gosseries O, Laureys S; Coma Science Group collaborators. The repetition of behavioral assessments in diagnosis of disorders of consciousness. Ann Neurol. 2017 Jun;81(6):883-889. doi: 10.1002/ana.24962. PubMed 28543735 ↗
  • Schnakers C, Vanhaudenhuyse A, Giacino J, Ventura M, Boly M, Majerus S, Moonen G, Laureys S. Diagnostic accuracy of the vegetative and minimally conscious state: clinical consensus versus standardized neurobehavioral assessment. BMC Neurol. 2009 Jul 21;9:35. doi: 10.1186/1471-2377-9-35. PubMed 19622138 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.

Of 16 observational studies under Persistent Vegetative State, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 6, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Mar 31, 2028
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07456020
Lead sponsor
BDH-Klinik Hessisch Oldendorf
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Feb 1, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Mar 11, 2026

Study contacts

Melanie Boltzmann, PhD
Contact
m.boltzmann@bdh-klinik-hessisch-oldendorf.de
+49 5152781256
Simone B. Jenner
Contact
s.jenner@bdh-klinik-hessisch-oldendorf.de
+49 5152781215
Melanie Boltzmann, PhD
principal investigator · BDH-Klinik Hessisch Oldendorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion